Photo of Prof Pat Eyers

Prof Pat Eyers BSc/PhD

Professor of Cell Signalling Biochemistry

    Biography

    Personal Statement

    Pat is Professor of Cell Signalling in the Department of Biochemistry, Institute of Integrative Biology at the University of Liverpool, where he runs a multidisciplinary lab. He obtained an undergraduate degree in Biochemistry at the University of Bristol, and completed his PhD with Sir Philip Cohen at the University of Dundee. After 4 years of postdoctoral research in the USA, he set up his laboratory in the UK with an MRC Career Development Fellowship in 2005. His interests include all aspects of protein phosphorylation and the analysis of protein kinase regulation, human pseudokinases and pseudoenzymes, and kinome-wide mechanisms of acquired drug resistance in cancer cells. He also teaches medical biochemistry, and runs modules exploring the biochemical mechanisms underpinning cell signalling.

    Career research highlights include:

    1) KInome-wide drug responses in human breast, lung and uveal cancer models (2017)
    2) Paradigm-shifting PKA holoenzyme:AKAP complex analysis and cAMP signalling (2016-)
    3) Analysis of protein pseudokinases, their co-factors and small molecule ligands (2014-)
    4) Aurora A as a therapeutic target in small cell lung cancer (2011)
    5) Drug-resistant Aurora, Polo-like and Mps1 kinases for drug target-validation (2010/11/17)
    6) Crystal structures, inhibitors and phosphoregulation of Mps1 (2008)

    7) Conserved rate-limiting roles for PKA, PLK4 and TPX2 in Xenopus cell cycles (2005, 2008)
    8) Purification and discovery of TPX2, a physiological activator of Aurora A (2003)
    9) Cellular ‘target-validation’ of p38 MAPK inhibitors using chemical genetic approaches (2000)
    10) First description of paradoxical activation of RAF kinases by chemical RAF inhibitors (1999)
    11) Co-discovery of the 'gatekeeper' residue in Ser/Thr kinases (1998)




    Personal Distinctions

    • Research Seminar (Invitation to Speak, School of Medical Sciences, University of Bangor 2017)
    • BBSRC Pool of Experts Panel D (BBSRC 2017)
    • Research Seminar (Invitation to Speak, University of Buenos Aires, Argentina 2017)
    • Research seminar (Invitation to Speak, North West Cancer Research Science Symposium 2017)
    • Invited Oral Presentation (Invitation to Speak, FASEB meeting (Protein Kinases and Protein Phosphorylation), Cambridge, UK 2017)
    • Research Seminar (Invitation to Speak, Babraham Institute, Cambridge 2017)
    • Pseudoenzymes 2016: from signalling mechanisms to disease (Biochemical Society Focussed Meeting 2016)
    • 2nd Kinase Inhibitors Design & Screening Conference (Invitation to Speak, Berlin, Germany 2016)
    • XXIV EFMC International Symposium on Medicinal Chemistry (Invitation to Speak, University of Manchester 2016)
    • Tribbles pseudokinases on the crossroads (Invitation to Speak, Biochemical Society, Budapest, Hungary 2015)
    • Kinases and Pseudokinases: spines, scaffolds and molecular switches (Invitation to Speak, ASBMB, San Diego, CA 2015)
    • Liverpool Enzyme Assay and Screening Facility (Department of Biochemistry, University of Liverpool 2015)
    • Exploring kinomes: Pseudokinases and beyond (Invitation to Speak, University of Cambridge 2013)
    • Drug-resistance mechanisms in protein kinases (Invitation to Speak, Institute for Cancer Research (ICR) 2013)
    • Mps1 kinase: a new validated oncology target (Invitation to Speak, Nervianos Sciences 2011)
    • MRC Career Development Fellowship (Competitive Fellowship, Medical Research Council 2006)

    Administrative Roles

    • Deputy Head, Department of Biochemistry
    • Institute Staff Review and Development Committee
    • Director and academic lead of the Liverpool Enzyme Screening And Assay Facility. This facility provides an academic and commercial service for enzyme studies using differential analysis of modified fluorescent peptides. In 2014, we acquired a Perkin Elmer Caliper EZ Reader II system, and have access to multiple kinase inhibitor and FDA-approved drug libraries for screening using a huge number of enzyme and substrate pairings.
    • Radiation Protection Officer and Site Safety Committee

    Untitled Document